1. Home
  2. WRN vs LUNG Comparison

WRN vs LUNG Comparison

Compare WRN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WRN
  • LUNG
  • Stock Information
  • Founded
  • WRN 2006
  • LUNG 1995
  • Country
  • WRN Canada
  • LUNG United States
  • Employees
  • WRN N/A
  • LUNG N/A
  • Industry
  • WRN Metal Mining
  • LUNG Industrial Specialties
  • Sector
  • WRN Basic Materials
  • LUNG Health Care
  • Exchange
  • WRN Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • WRN 237.4M
  • LUNG 243.2M
  • IPO Year
  • WRN N/A
  • LUNG 2020
  • Fundamental
  • Price
  • WRN $1.03
  • LUNG $6.80
  • Analyst Decision
  • WRN Strong Buy
  • LUNG Buy
  • Analyst Count
  • WRN 1
  • LUNG 6
  • Target Price
  • WRN $4.25
  • LUNG $11.92
  • AVG Volume (30 Days)
  • WRN 188.2K
  • LUNG 236.5K
  • Earning Date
  • WRN 11-07-2024
  • LUNG 02-19-2025
  • Dividend Yield
  • WRN N/A
  • LUNG N/A
  • EPS Growth
  • WRN N/A
  • LUNG N/A
  • EPS
  • WRN N/A
  • LUNG N/A
  • Revenue
  • WRN N/A
  • LUNG $79,302,000.00
  • Revenue This Year
  • WRN N/A
  • LUNG $22.26
  • Revenue Next Year
  • WRN N/A
  • LUNG $18.72
  • P/E Ratio
  • WRN N/A
  • LUNG N/A
  • Revenue Growth
  • WRN N/A
  • LUNG 22.34
  • 52 Week Low
  • WRN $0.95
  • LUNG $5.46
  • 52 Week High
  • WRN $1.66
  • LUNG $14.84
  • Technical
  • Relative Strength Index (RSI)
  • WRN 40.70
  • LUNG 48.12
  • Support Level
  • WRN $0.99
  • LUNG $5.72
  • Resistance Level
  • WRN $1.14
  • LUNG $6.38
  • Average True Range (ATR)
  • WRN 0.04
  • LUNG 0.34
  • MACD
  • WRN -0.00
  • LUNG 0.01
  • Stochastic Oscillator
  • WRN 20.00
  • LUNG 45.76

About WRN Western Copper and Gold Corporation

Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: